Why the study?
Does combination chemotherapy improve clinical status and tumor response in patients with pulmonary epithelioid hemangioendothelioma?
Does combination chemotherapy improve clinical status and tumor response in patients with pulmonary epithelioid hemangioendothelioma?
Combination chemotherapy regimens may hold therapeutic potential for the treatment of the rare disease pulmonary epithelioid hemangioendothelioma.
Hypothesis-generating for chemotherapy in pulmonary epithelioid hemangioendothelioma; prospective trials needed before clinical adoption.
No standard therapy for pulmonary epithelioid hemangioendothelioma (PEH) has yet been established due to the rarity of the disease, the lack of clear standards for treatment and the partial-to-complete spontaneous regression. This report describes three cases of PHE manifested as bilateral intrapulmonary masses with an initial diagnosis conducted by thoracoscopic lung biopsy. These patients demonstrated a partial response to combination chemotherapy with carboplatin, paclitaxel, bevacizumab or endostar, and an improvement in clinical status. Furthermore, we reviewed the literature regarding such patients who received chemotherapy and immunotherapy; this indicated that patients with PEH demonstrated a good partial response to chemotherapy with carboplatin, paclitaxel, bevacizumab, thalidomide and α-interferon. Overall, combination chemotherapy regimens may hold therapeutic potential for the treatment of this rare disease.
No takes yet. Share an insight, caveat, or question.
Ye et al. (2013) studied this question.
Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context: